The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Januvia

25 milligram(s) Tablet

Merck Sharp and Dohme LimitedEU/1/07/383/1-6

Main Information

Trade NameJanuvia
Active SubstancesSitagliptin phosphate monohydrate
Strength25 milligram(s)
Dosage FormTablet
Licence HolderMerck Sharp and Dohme Limited
Licence NumberEU/1/07/383/1-6

Group Information

ATC CodeA10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH01 sitagliptin

Status

Authorised/WithdrawnAuthorised
Licence Issued21/03/2007
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back